Administration route |
intravenous infusion |
Dosage |
600 mg, three loading doses within a 9-day period, then 600 mg on Days 1, 8 and 15 ofEach 21-day cycle |
Pts |
99 |
Age |
Adult, Older_Adult |
Adverse reactions |
78/99(All-cause mortality); 56/99(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Infections and infestations; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Psychiatric disorders; Renal and urinary disorders; Reproductive system and breast disorders; Vascular disorders) |
|